Contract award for over 100,000 eligible employees marks Dario&#39;s fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition managementProgram

<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">Contract award for over 100,000 eligible employees marks Dario&#39;s fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition management</i></p><p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">Program expected to launch Fall 2026, with revenue contribution beginning by year-end and ramping through 2027</i></p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">July 16, 2026</span> /PRNewswire/ -- <b xmlns="http://www.w3.org/1999/xhtml">DarioHealth Corp. </b>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DRIO">DRIO</a>) (the &#34;Company&#34;, &#34;DarioHealth&#34; or &#34;Dario&#34;), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/or hypertension. The program will be available to more than 100,000 eligible employees and is expected to launch in Fall 2026. Eligible members will receive a unified care experience that combines connected devices, personalized human coaching, AI-driven insights via DarioIQ&#x2122; and behavior change support within a single platform.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1783583/Dario-Logo.jpg?id=OA2765116" title="DarioHealth Corp. Logo" alt="DarioHealth Corp. Logo"></img>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">Annual recurring revenue from the program is expected to begin by the end of 2026 following implementation, with increasing contribution anticipated throughout 2027 and beyond.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;Winning another Fortune 50 employer underscores the growing recognition that integrated chronic condition management delivers better outcomes than treating each condition independently, resulting in clinically significant outcomes and economic impact,&#34; said Erez Raphael, Chief Executive Officer of Dario. &#34;The value we deliver to the largest enterprises in the world is evident in the fact that nearly one-quarter of our clients today are Fortune 500 companies.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;Employers continue to focus on managing healthcare costs while simultaneously improving health outcomes. Our AI-enabled multi-condition platform, powered by DarioIQ, is uniquely positioned to deliver on both objectives,&#34; added Lara Dodo, Dario&#39;s Chief Operating Officer.</p><p xmlns="http://www.w3.org/1999/xhtml">Unlike traditional point solutions that manage individual conditions, Dario&#39;s integrated chronic condition platform is designed to address comorbidities, including <a xmlns="http://www.w3.org/1999/xhtml" href="https://diabetesjournals.org/care/article/47/1/26/153797/Economic-Costs-of-Diabetes-in-the-U-S-in-2022" target="_blank" rel="nofollow">diabetes</a> and <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html" target="_blank" rel="nofollow">hypertension</a>, two of the most prevalent and costly chronic diseases that frequently occur together – costing a combined $500+ billion in U.S. healthcare costs annually.  <a xmlns="http://www.w3.org/1999/xhtml" href="https://diabetesjournals.org/diabetes/article/72/Supplement_1/1069-P/150509/1069-P-Digital-Platform-Users-Managing-Three" target="_blank" rel="nofollow">Published research shows</a> that members on Dario&#39;s digital platform managing three chronic conditions (diabetes, hypertension and overweight) simultaneously experience better outcomes than those who manage just one condition. </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About DarioHealth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DRIO">DRIO</a>)</b></p><p xmlns="http://www.w3.org/1999/xhtml">DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DRIO">DRIO</a>) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company&#39;s integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.</p><p xmlns="http://www.w3.org/1999/xhtml">Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario&#39;s AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Cautionary Note Regarding Forward-Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when the expected launch and implementation of the program; the anticipated availability of the program to more than 100,000 eligible employees; expected member enrollment and utilization; the timing and amount of anticipated recurring revenue, including revenue expected to begin in late 2026 and increase throughout 2027 and beyond; the expected clinical and economic benefits of the Company&#39;s integrated cardiometabolic care platform and DarioIQ&#x2122;; the anticipated demand for integrated chronic condition management solutions among employers; the Company&#39;s ability to successfully implement the program and expand relationships with enterprise customers; and the Company&#39;s future business, growth and commercial prospects. Without limiting the generality of the foregoing, words such as &#34;plan,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;seek,&#34; &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;could,&#34; &#34;estimate&#34; or &#34;continue&#34; are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company&#39;s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company&#39;s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company&#39;s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company&#39;s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company&#39;s commercial and regulatory plans for Dario&#x2122; as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">DarioHealth Corporate Contacts<br xmlns="http://www.w3.org/1999/xhtml"></br></b>Michael Lipari<br xmlns="http://www.w3.org/1999/xhtml"></br>SVP Corporate Development<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:irteam@dariohealth.com" target="_blank" rel="nofollow">irteam@dariohealth.com</a><br xmlns="http://www.w3.org/1999/xhtml"></br>+1-201-785-6310</p><p xmlns="http://www.w3.org/1999/xhtml">Rob Halpern<br xmlns="http://www.w3.org/1999/xhtml"></br>SVP Marketing<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:irteam@dariohealth.com" target="_blank" rel="nofollow">irteam@dariohealth.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LN05362&amp;sd=2026-07-16"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/fortune-50-employer-awards-dario-contract-to-deliver-ai-powered-cardiometabolic-care-platform-302826580.html" target="_blank">https://www.prnewswire.com/news-releases/fortune-50-employer-awards-dario-contract-to-deliver-ai-powered-cardiometabolic-care-platform-302826580.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE DarioHealth Corp.</p>

DRIO

Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform

Dario Health secures Fortune 50 contract for 100k employees, revenue ramp in 2026-27

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Contract award for over 100,000 eligible employees marks Dario&amp;#39;s fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition managementProgram</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>DarioHealth today announced a Fortune 50 employer contract to deploy its AI-powered cardiometabolic platform for over 100,000 employees, with a Fall 2026 launch and recurring revenue starting by year-end 2026 and growing through 2027. The deal highlights demand for integrated chronic-condition management among large employers and could boost DRIO’s enterprise traction and near-term revenue visibility, supporting longer-term ARR expansion.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Fortune 50 employer contract for 100k employees. Fall 2026 launch.</li><li>ARR to begin by end-2026; ramping through 2027.</li><li>CEO: integrated platform improves outcomes; nearly 25% of clients are Fortune 500.</li><li>Unified platform combines devices, coaching, AI insights.</li><li>Diabetes and hypertension drive $500B+ U.S. costs; DRIO addresses co-morbidities.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>DarioHealth Corp. (DRIO)</strong>: Announces contract; fifth Fortune 50 client; enhances revenue visibility and enterprise exposure.</li><li><strong>Fortune 50 Employer (unnamed) (N/A)</strong>: Large-scale deployment validates demand for integrated cardiometabolic platform.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article reports a large enterprise contract win for DRIO, signaling growing traction with Fortune 50 customers and potential for sustained ARR growth.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>New Fortune 50 deal expands addressable ARR and validates enterprise traction.</li><li>Near-term catalyst as Fall 2026 launch enables year-end ARR recognition.</li><li>DRIO gains credibility among large employers; potential for further Fortune 50 wins.</li><li>Integrated, multi-condition platform may pressure traditional, single-condition solutions.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Contract covers more than 100,000 eligible employees.</li><li>Program expected to launch Fall 2026.</li><li>ARR to begin by end-2026 with ramp through 2027.</li><li>This is DRIO&#039;s fifth Fortune 50 client.</li><li>DarioHealth platform integrates connected devices, coaching, and AI insights.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish over 12-24 months as enterprise deals scale and ARR ramps.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">Contract award for over 100,000 eligible employees marks Dario&#39;s fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition management</i></p><p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">Program expected to launch Fall 2026, with revenue contribution beginning by year-end and ramping through 2027</i></p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">July 16, 2026</span> /PRNewswire/ -- <b xmlns="http://www.w3.org/1999/xhtml">DarioHealth Corp. </b>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DRIO">DRIO</a>) (the &#34;Company&#34;, &#34;DarioHealth&#34; or &#34;Dario&#34;), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/or hypertension. The program will be available to more than 100,000 eligible employees and is expected to launch in Fall 2026. Eligible members will receive a unified care experience that combines connected devices, personalized human coaching, AI-driven insights via DarioIQ&#x2122; and behavior change support within a single platform.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1783583/Dario-Logo.jpg?id=OA2765116" title="DarioHealth Corp. Logo" alt="DarioHealth Corp. Logo"></img>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">Annual recurring revenue from the program is expected to begin by the end of 2026 following implementation, with increasing contribution anticipated throughout 2027 and beyond.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;Winning another Fortune 50 employer underscores the growing recognition that integrated chronic condition management delivers better outcomes than treating each condition independently, resulting in clinically significant outcomes and economic impact,&#34; said Erez Raphael, Chief Executive Officer of Dario. &#34;The value we deliver to the largest enterprises in the world is evident in the fact that nearly one-quarter of our clients today are Fortune 500 companies.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;Employers continue to focus on managing healthcare costs while simultaneously improving health outcomes. Our AI-enabled multi-condition platform, powered by DarioIQ, is uniquely positioned to deliver on both objectives,&#34; added Lara Dodo, Dario&#39;s Chief Operating Officer.</p><p xmlns="http://www.w3.org/1999/xhtml">Unlike traditional point solutions that manage individual conditions, Dario&#39;s integrated chronic condition platform is designed to address comorbidities, including <a xmlns="http://www.w3.org/1999/xhtml" href="https://diabetesjournals.org/care/article/47/1/26/153797/Economic-Costs-of-Diabetes-in-the-U-S-in-2022" target="_blank" rel="nofollow">diabetes</a> and <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html" target="_blank" rel="nofollow">hypertension</a>, two of the most prevalent and costly chronic diseases that frequently occur together – costing a combined $500+ billion in U.S. healthcare costs annually.  <a xmlns="http://www.w3.org/1999/xhtml" href="https://diabetesjournals.org/diabetes/article/72/Supplement_1/1069-P/150509/1069-P-Digital-Platform-Users-Managing-Three" target="_blank" rel="nofollow">Published research shows</a> that members on Dario&#39;s digital platform managing three chronic conditions (diabetes, hypertension and overweight) simultaneously experience better outcomes than those who manage just one condition. </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About DarioHealth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DRIO">DRIO</a>)</b></p><p xmlns="http://www.w3.org/1999/xhtml">DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DRIO">DRIO</a>) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company&#39;s integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.</p><p xmlns="http://www.w3.org/1999/xhtml">Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario&#39;s AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Cautionary Note Regarding Forward-Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when the expected launch and implementation of the program; the anticipated availability of the program to more than 100,000 eligible employees; expected member enrollment and utilization; the timing and amount of anticipated recurring revenue, including revenue expected to begin in late 2026 and increase throughout 2027 and beyond; the expected clinical and economic benefits of the Company&#39;s integrated cardiometabolic care platform and DarioIQ&#x2122;; the anticipated demand for integrated chronic condition management solutions among employers; the Company&#39;s ability to successfully implement the program and expand relationships with enterprise customers; and the Company&#39;s future business, growth and commercial prospects. Without limiting the generality of the foregoing, words such as &#34;plan,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;seek,&#34; &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;could,&#34; &#34;estimate&#34; or &#34;continue&#34; are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company&#39;s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company&#39;s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company&#39;s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company&#39;s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company&#39;s commercial and regulatory plans for Dario&#x2122; as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">DarioHealth Corporate Contacts<br xmlns="http://www.w3.org/1999/xhtml"></br></b>Michael Lipari<br xmlns="http://www.w3.org/1999/xhtml"></br>SVP Corporate Development<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:irteam@dariohealth.com" target="_blank" rel="nofollow">irteam@dariohealth.com</a><br xmlns="http://www.w3.org/1999/xhtml"></br>+1-201-785-6310</p><p xmlns="http://www.w3.org/1999/xhtml">Rob Halpern<br xmlns="http://www.w3.org/1999/xhtml"></br>SVP Marketing<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:irteam@dariohealth.com" target="_blank" rel="nofollow">irteam@dariohealth.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LN05362&amp;sd=2026-07-16"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/fortune-50-employer-awards-dario-contract-to-deliver-ai-powered-cardiometabolic-care-platform-302826580.html" target="_blank">https://www.prnewswire.com/news-releases/fortune-50-employer-awards-dario-contract-to-deliver-ai-powered-cardiometabolic-care-platform-302826580.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE DarioHealth Corp.</p>

DarioHealth today announced a Fortune 50 employer contract to deploy its AI-powered cardiometabolic platform for over 100,000 employees, with a Fall 2026 launch and recurring revenue starting by year-end 2026 and growing through 2027. The deal highlights demand for integrated chronic-condition management among large employers and could boost DRIO’s enterprise traction and near-term revenue visibility, supporting longer-term ARR expansion.

Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News